OmniAb, Inc. (NASDAQ:OABI - Get Free Report) CFO Kurt A. Gustafson sold 6,954 shares of the business's stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $5.27, for a total transaction of $36,647.58. Following the completion of the transaction, the chief financial officer now directly owns 176,697 shares of the company's stock, valued at approximately $931,193.19. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
OmniAb Price Performance
NASDAQ OABI opened at $5.43 on Wednesday. OmniAb, Inc. has a 12 month low of $3.14 and a 12 month high of $6.72. The company has a 50-day moving average of $5.50 and a 200-day moving average of $5.34. The company has a market cap of $635.99 million, a P/E ratio of -10.65 and a beta of -0.18.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of OABI. Stephens Inc. AR acquired a new position in shares of OmniAb during the 1st quarter valued at about $32,000. Stifel Financial Corp purchased a new stake in shares of OmniAb during the 1st quarter worth about $37,000. Federated Hermes Inc. purchased a new stake in shares of OmniAb during the 4th quarter worth about $38,000. Two Sigma Advisers LP purchased a new stake in shares of OmniAb during the 1st quarter worth about $47,000. Finally, HighTower Advisors LLC purchased a new stake in shares of OmniAb during the 1st quarter worth about $48,000. Institutional investors and hedge funds own 72.08% of the company's stock.
Wall Street Analysts Forecast Growth
Healthcare Takes A Big Step Forward With The Help Of AI
From The Bull Report | Ad
The average doctor can diagnose an illness correctly 50-90% of the time.
But one innovative company's medical AI gets it right 92%+.
Click here to see why this small company is trusted by the Mayo Clinic
Several research analysts recently weighed in on OABI shares. Royal Bank of Canada reissued an "outperform" rating and issued a $7.00 target price on shares of OmniAb in a research note on Thursday, March 21st. HC Wainwright reissued a "buy" rating and issued a $11.00 target price on shares of OmniAb in a research note on Thursday, March 21st. Benchmark reissued a "buy" rating and issued a $8.00 target price on shares of OmniAb in a research note on Friday, March 22nd. Finally, Truist Financial reissued a "buy" rating and issued a $10.00 target price on shares of OmniAb in a research note on Tuesday, March 26th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $9.20.
Get Our Latest Report on OABI
OmniAb Company Profile
(
Get Free Report)
OmniAb, Inc, a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
